Emalex Biosciences
Manufacturing · Illinois, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
330 N Wabash Ave Ste 3500, Chicago, Illi...Phone Number
(312) 847-1340Website
www.emalexbiosciences.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Emalex Biosciences
Emalex Biosciences is a biotechnology company focused on developing innovative treatments for central nervous system disorders, specifically targeting Tourette syndrome. The company is currently conducting late-stage clinical studies for a new class of drug aimed at patients with limited treatment options. Emalex is committed to providing relief for individuals suffering from Tourette syndrome, addressing both the physical and emotional challenges associated with the condition. Their lead candidate has shown promising results in clinical trials, demonstrating statistical significance in efficacy for both pediatric and adult subjects.Explore more
Emalex Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Emalex Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Emalex Biosciences had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Emalex Biosciences
Check out if Emalex Biosciences is spiking on competitors!
Check if Emalex Biosciences has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Emalex Biosciences launches new products
Emalex Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Emalex Biosciences has new funding data
Earning: See what the market has to say on Emalex Biosciences recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Emalex Biosciences as Masked Content
Find 3 more new buyers
Compare Similar Companies to Emalex Biosciences
Compare insights from companies similar to Emalex Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Emalex Biosciences
<$5M
11-50
Private
$555M
2018
PR
Paul ReinfeldsSenior Vice President - Legal Affairs and General Counsel
Company Profile Activity
Activity Insights
Emalex Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Emalex Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Emalex Biosciences.
Emalex Biosciences financials insights
Gather financial insights about Emalex Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series C
$35M
2022
Series D
$250M
2025
Private Equity
$270M
Emalex Biosciences Tech Stack
A closer look at the technologies used by Emalex Biosciences
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
, according to a recent Form D filing, has secured $270,000,000 in Private Equity funding.
Funding
Funding
Emalex Biosciences News & Media
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
CHICAGO--(BUSINESS WIRE)--Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with Tourette syndrome.Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate
CHICAGO--(BUSINESS WIRE)--Long-term safety data from pediatric patients treated with investigational drug ecopipam highlighted at Child Neurology Society Meeting in Vancouver.Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe CHICAGO, March 1, 2023 /PRNewswire/ -- Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for the treatment of Tourette...Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
Study data shows investigational new drug, ecopipam, reduced total number of tics by 30% compared to placebo CHICAGO, Jan. 11, 2023 /PRNewswire/ -- A Phase 2b clinical trial involving more than 150 children and adolescents with Tourette syndrome found ecopipam significantly reduced the...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Emalex Biosciences
Sign Up For FreeTo access detailed company insights
Emalex Biosciences is a biotechnology company focused on developing innovative treatments for central nervous system disorders, specifically targeting Tourette syndrome. The company is currently conducting late-stage clinical studies for a new class of drug aimed at patients with limited treatment options. Emalex is committed to providing relief fo... Read More
